Afficher la notice abrégée

dc.creatorPapatheodoridis, G. V.en
dc.creatorDalekos, G. N.en
dc.creatorSypsa, V.en
dc.creatorYurdaydin, C.en
dc.creatorButi, M.en
dc.creatorGoulis, I.en
dc.creatorChi, H.en
dc.creatorManolakopoulos, S.en
dc.creatorMangia, G.en
dc.creatorGatselis, N.en
dc.creatorKeskin, O.en
dc.creatorSavvidou, S.en
dc.creatorHansen, B. E.en
dc.creatorVlachogiannakos, J.en
dc.creatorGalanis, K.en
dc.creatorIdilman, R.en
dc.creatorColombo, M.en
dc.creatorEsteban, R.en
dc.creatorJanssen, H. L.en
dc.creatorLampertico, P.en
dc.date.accessioned2015-11-23T10:44:27Z
dc.date.available2015-11-23T10:44:27Z
dc.date.issued2014
dc.identifier.issn0270-9139
dc.identifier.urihttp://hdl.handle.net/11615/31946
dc.source.uri<Go to ISI>://WOS:000344483801167
dc.subjectGastroenterology & Hepatologyen
dc.titleTiming of hepatocellular carcinoma (HCC) development and predictability of a modified PAGE-B risk score in caucasian chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir (TDF)en
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée